A panel discussion during the JPMorgan conference earlier this month examined where oncology drug development is headed, driven in part by advances in diagnostic testing.
The following is a summary of “Expression and prognostic value of ferritinophagy-related NCOA4 gene in low-grade glioma: ...
Calidi Biotherapeutics (NYSE American: CLDI) , a clinical-stage biotechnology company advancing targeted antitumor virotherapies, will host an invest ...
SAN DIEGO, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor ...
Calidi Biotherapeutics (NYSE American: CLDI) , a clinical-stage biotechnology company specializing in targeted antitumor virotherapies, reported a ca ...
In connection with the SEPA executed in December 2023 and amended in January 2024, Calidi was granted the option to sell up to $25 million of common stock over a three-year period, subject to certain ...
A group led by the Department of Neurosurgery, Brain Research Institute, Niigata University, has succeeded in the diagnosis ...
Diagnosis of Leptomeningeal Disease in Diffuse Midline Gliomas by Detection of H3F3A K27M Mutation in Circulating Tumor DNA ...
Patients with a glioma, a type of malignant brain tumor, can suffer from cognitive problems after surgery. However, the true ...
ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation and CellReady, today announced that ...
Cecile Richards, a prominent advocate for women's rights and other progressive causes and former President of Planned ...
Explore the role of preclinical MRI in studying neurological diseases, with a focus on advanced cellular and molecular ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback